Skip to main content

Innovent and Lilly Announce China Approval for Rituxan Biosimilar

Suzhou Innovent Bio and Eli Lilly announced their Rituxan biosimilar was approved in China for lymphoma and leukemia indications. Halpryza® (rituximab injection) is Innovent's fourth mAb approved for China use. It is a recombinant human/murine chimeric monoclonal antibody drug that was co-developed by Innovent and Lilly. The biosimilar is indicated for China patients with diffuse large b cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. More details.... Stock Symbols: (HK: 01801) (NYSE: LLY) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.